Original Article
Brief Report
Stem-Cell Gene Therapy for the Wiskott–Aldrich Syndrome
N Engl J Med 2010; 363:1918-1927November 11, 2010
- Abstract
The Wiskott–Aldrich syndrome (WAS) is an X-linked recessive primary immunodeficiency disorder associated with thrombocytopenia, eczema, and autoimmunity. We treated two patients who had this disorder with a transfusion of autologous, genetically modified hematopoietic stem cells (HSC). We found sustained expression of WAS protein expression in HSC, lymphoid and myeloid cells, and platelets after gene therapy. T and B cells, natural killer (NK) cells, and monocytes were functionally corrected. After treatment, the patients' clinical condition markedly improved, with resolution of hemorrhagic diathesis, eczema, autoimmunity, and predisposition to severe infection. Comprehensive insertion-site analysis showed vector integration that targeted multiple genes controlling growth and immunologic responses in a persistently polyclonal hematopoiesis. (Funded by Deutsche Forschungsgemeinschaft and others; German Clinical Trials Register number, DRKS00000330.)
Media in This Article
Figure 1
Restored Expression of Wiskott–Aldrich Syndrome (WAS) Protein (WASP) after Gene Therapy.Figure 2
Correction of Leukocyte Function after Gene Therapy (GT).Article Activity
- Article
The Wiskott–Aldrich syndrome (WAS) is a complex primary immunodeficiency disorder that is characterized by recurrent infections, thrombocytopenia, eczema, and autoimmunity1,2 and caused by mutations in WAS.3 Its gene product, WAS protein (WASP), is a key regulator of actin polymerization in hematopoietic cells, with domains involved in signaling, cell locomotion, and immunologic-synapse formation.4 The complex biologic features of this disease result from multiple dysfunctions in different subgroups of leukocytes, including defective function of T and B cells, disturbed formation of the NK-cell immunologic synapse, and impaired migratory responses in all leukocyte subgroups.4,5 Severe WAS leads to an early death from infection or bleeding.6 Currently, the only curative therapy consists of allogeneic HSC transplantation, which may be associated with considerable risk of death or complications related to transplantation.7
HSC gene therapy has emerged as an innovative therapeutic strategy for various primary immunodeficiency disorders.8-12 WAS is a promising candidate disease for gene-therapy approaches, since WASP expression is restricted to cells of the hematopoietic system, which grants a proliferative advantage over WASP-negative cells.13,14 Preclinical studies have shown efficient reconstitution of cellular function in vitro and in vivo.13 On the basis of our own preclinical in vitro and in vivo studies,15,16 we developed a clinical gene-transfer protocol.13 Here we report the results in two young boys who were treated with HSC gene therapy.
Methods
Study Design
The clinical gene-therapy protocol was reviewed by local and federal authorities, in accordance with current regulations of the European Community. Inclusion criteria for the study included an age of at least 12 months, a diagnosis of severe WAS (as documented by molecular and clinical phenotype), no indication of malignant disease before gene therapy, documentation of informed consent or informed assent, and isolation of a sufficient number of vital CD34+ cells from bone marrow or leukapheresis. Two 3-year-old boys who had been referred for gene therapy fulfilled the inclusion criteria, and their parents provided written informed consent.
Study Oversight
The trial was conducted in compliance with the Good Clinical Practice guidelines of the European Clinical Trials Directive and the provisions of the Declaration of Helsinki. A detailed description of the technical methods that were used in the study is provided in the Supplementary Appendix, available with the full text of this article at NEJM.org.
Results
Patients
Patient 1 presented with hematoma and petechiae after birth, and within the first year of life, hemorrhagic colitis, eczema, and therapy-refractory autoimmune hemolytic anemia developed. In addition, he had autoimmune neutropenia and recurrent infections (bronchitis, otitis media, and enterocolitis). Molecular analysis revealed a splice site mutation in WAS, IVS6+1. No residual protein or somatic chimerism was detectable (Figure 1 in the Supplementary Appendix).
Patient 2 presented with thrombocytopenia and hemorrhagic diathesis soon after birth. He had recurrent episodes of upper respiratory tract infection, life-threatening salmonella septicemia, and eczema that was not responsive to local and systemic therapy. Molecular studies revealed a known mutation in WAS (c. G257A, p. Arg86His).3,6 No residual protein or somatic chimerism was detectable (Figure 1 in the Supplementary Appendix).
Gene Transfer
We collected autologous CD34+ HSCs by leukapheresis. The cells were then transduced with WASP-expressing retroviral vectors that were created with backbone vector CMMP and pseudotyped with gibbon ape leukemia virus (GALV) envelope protein; the cells were then reinfused 4 days later (Table 1 in the Supplementary Appendix). Before reinfusion of CD34+ cells, busulfan was administered at a dose of 4 mg per kilogram of body weight per day on days 3 and 2 before the procedure. Transient myelosuppression and partial alopecia were observed as therapy-associated side effects. For details regarding the vector that was used and the clinical gene-therapy protocol, see the Supplementary Appendix.
Restoration of WAS Expression
After gene therapy, WASP-positive cells in various leukocyte subgroups were detected on flow cytometry (Figure 1A and 1BFigure 1
Restored Expression of Wiskott–Aldrich Syndrome (WAS) Protein (WASP) after Gene Therapy.). The frequency of WASP-positive monocytes, initially detected soon after gene therapy, has remained stable at 7 to 28%. An increased percentage of lymphoid cells were WASP-positive, consistent with a known proliferative advantage conferred by WASP expression in that lineage.14 The level of WASP-positive NK cells ranged from 25 to 90% over time. An increase in the percentage of WASP-positive CD4+ and CD8+ T cells was seen 6 to 12 months after gene therapy and has remained stable ever since. Restoration of WASP expression in peripheral-blood mononuclear cells was confirmed on Western blot analyses (Figure 1C and 1D).At the level of hematopoietic progenitor cells, a stable chimerism was found in the bone marrow of both patients, with 9% of CD34+ cells expressing the WASP transgene in Patient 1 and 20% in Patient 2 (Figure 2 in the Supplementary Appendix). The presence of vector-positive cells in all leukocyte subgroups at different time points after gene therapy was confirmed on quantitative polymerase-chain-reaction (PCR) assay (Figure 3 in the Supplementary Appendix). PCR analysis of colony-forming units from both patients confirmed vector integrations in 3 of 101 colonies in Patient 1 and in 23 of 103 colonies in Patient 2 (data not shown).
An increase in platelet counts was noted, starting 6 to 9 months after gene therapy, which marked the end of episodes of clinical bleeding (Figure 1E and 1F). On the most recent follow-up, 2.5 years after gene therapy, platelet counts were 256,000 for Patient 1 and 88,000 for Patient 2. WASP expression in platelet-rich plasma from both patients was confirmed on Western blot and flow cytometric analysis (Figure 1G and 1H, and Figure 4 in the Supplementary Appendix).
Correction of Defective Leukocyte Function
We next analyzed whether restored WASP expression would lead to improved leukocyte function. In NK cells, WASP deficiency leads to a decreased accumulation of F-actin and perforin at the NK-cell immunologic synapse,17 which reduces NK-cell–mediated cytotoxicity. After gene therapy, substantial proportions of the NK-cell immunologic synapses were restored in both patients (Figure 2AFigure 2
Correction of Leukocyte Function after Gene Therapy (GT)., and Figure 5 and Figure 6 in the Supplementary Appendix), and NK-cell lytic activity was reconstituted (Figure 2B). WASP-deficient monocytes and dendritic cells are characterized by the inability to form podosomes.4 The fraction of podosome-positive monocytes after gene transfer ranged from 8 to 34% (Figure 2C, and Figure 7 in the Supplementary Appendix), indicating that restored WASP expression reconstituted the capacity to rearrange the cytoskeleton in myeloid cells.T-cell abnormalities in patients with WAS include diminished T-cell proliferative responses and a skewed antigen-recognition repertoire for T-cell receptors.4 After gene therapy, T-cell proliferative responses were reconstituted at multiple time points in both patients (Figure 2D, and Figure 8 in the Supplementary Appendix). Vβ gene spectratyping of T-cell receptors showed increasing polyclonality of TCR usage in both patients after gene therapy, as shown by a distribution pattern that was consistent with decreasing oligoclonal T-cell receptor Vβ rearrangements (Figure 2E, and Figure 9 in the Supplementary Appendix).
The percentage of WASP-expressing B cells increased over time after gene therapy, with proportions of WASP+CD19+ cells of 57% in Patient 1 and 69% in Patient 2 2.5 years after gene therapy. Abnormal immunoglobulin levels (increased IgM in Patient 1 and decreased IgG in Patient 2) normalized after gene therapy. Although normal immunoglobulin levels have remained stable in Patient 2, IgG levels have not remained at a protective level in Patient 1, who had undergone earlier splenectomy (Table 2 in the Supplementary Appendix). Both patients were immunized with hexavalent vaccine 12 months after gene therapy and successfully produced specific antibodies to tetanus, diphtheria, and Haemophilus influenzae (Table 3 in the Supplementary Appendix).
Infections and Autoimmunity
After gene therapy, the frequency and severity of infections decreased in both patients. However, 2 years after gene therapy, Patient 1 had an episode of pneumococcal meningitis, which was responsive to intravenous antibiotic treatment. Contributing factors may have been his previous splenectomy or insufficient B-cell reconstitution.
Signs and symptoms of autoimmunity disappeared in both patients within the first year after gene therapy. In Patient 1, severe autoimmune hemolytic anemia (with polyspecific anti-Jka antibodies), autoimmune thrombocytopenia (with antibodies directed against membrane glycoproteins IIb/IIIa, Ib/IX, and V), and autoimmune neutropenia (with antibodies against HNA-1a) disappeared (Table 4 in the Supplementary Appendix), and severe eczema resolved in Patient 2 (Figure 2F). Since recent studies have highlighted the role of regulatory T cells (Tregs) in controlling autoimmunity in WASP deficiency,18 we measured the relative proportion of WASP-expressing regulatory T cells. The percentage of WASP-positive cells in CD4+CD25+FOXP3+ cells was higher than in the nonregulatory T-cell population (CD4+CD25−FOXP3−) in both patients (Figure 11 in the Supplementary Appendix).
High-Resolution Analysis of Insertion Site
No morphologic or cytogenetic aberrations were seen in bone marrow aspirates after gene therapy. The clonal distribution and fate of gene-corrected cells in vivo were monitored by large-scale analyses of retroviral vector insertion sites with linear-amplification–mediated PCR (LAM-PCR),19 followed by 454 pyrosequencing. In both patients, a highly polyclonal reconstitution pattern was seen in bone marrow cells, primary blood leukocytes, lymph-node cells (analyzed in Patient 1), sorted lymphoid CD3+ T cells, and myeloid granulocytes (Figure 3A and 3BFigure 3
Sustained Polyclonal Hematopoietic Repopulation after Gene Therapy.). Of approximately 400,000 raw LAM-PCR amplicon sequence reads, 5709 unique retroviral insertion sites (in Patient 1) and 9538 sites (in Patient 2) were retrieved from bone marrow, lymph nodes, and primary blood leukocytes and could be mapped to a single position in the human genome. Vector integration occurred preferentially in the vicinity of transcription start sites and into gene coding regions of the human genome, reflecting a typical gammaretroviral target-site distribution (Figure 12 in the Supplementary Appendix).The abundance of individual gene-corrected cells and their clonal progeny in the hematopoietic system was estimated by the retrieval frequency of individual retroviral insertion site sequences generated by deep sequencing (Figure 3C and 3D). In both patients, several clones appeared repeatedly within the 10 most abundant clones in each analyzed time point, indicating that clonal skewing had emerged among active hematopoietic gene-corrected clones. Ingenuity pathway analyses in both patients revealed a substantial enrichment of genes that are involved in biologic processes regulating cellular development, growth, and proliferation, as well as hematopoiesis. More specifically, a substantial enrichment of vector insertions in or near genes regulating immune and autoimmune responses was observed in both patients (Figure 13 in the Supplementary Appendix).
We further monitored the genomic distribution of insertion sites that were clustered in subgenomic regions and associated with particular reference sequence (RefSeq) genes over time as an indicator of in vivo selection of gene-corrected cells. In both patients, the same multiple vector targeted genes that were previously found to expand clones in gene-corrected myelopoiesis (MDS1/EVI1, PRDM16, and SETBP1) and lymphopoiesis (LMO2, CCND2, and BMI1) were noted12,20-23 (Figure 3E and 3F). The most active cell clone in Patient 1 showed a vector integrant upstream of CCND2, and in Patient 2, the site of insertion was MDS1/EVI1 (Figure 4A and 4BFigure 4
Insertion Sites Clustered in Specific Gene Regions., and Table 5 in the Supplementary Appendix).Insertion-site analyses in sorted CD3+ lymphocytes and myeloid granulocytes revealed that the clonal contribution of cells with insertions in coincident insertion sites that have been found to trigger clonal expansion in gene-corrected lymphopoiesis and myelopoiesis was almost exclusively related to either lymphoid cells or myeloid cells (Figure 4C and 4D). In contrast, retroviral insertion sites that were identical between sorted lymphoid or myeloid cell fractions were also retrieved from both patients, at least 9000 times as frequently as expected by statistical chance alone. This marking indicates the initial transduction of cells with multilineage capacity (Table 6 in the Supplementary Appendix). Prospective monitoring for signs of clonal dominance in gene-corrected hematopoiesis will continue in both patients.
Discussion
Previous clinical studies of hematopoietic gene therapy have reported sustained or temporary correction of lymphocytes in patients with severe combined immunodeficiency or adrenoleukodystrophy8,9,24 and of myeloid cells in patients with chronic granulomatous disease or adrenoleukodystrophy.12,24 Our study shows that gene therapy for the Wiskott–Aldrich syndrome is feasible and has not been associated with treatment-limiting adverse events up to 3 years after gene therapy. These findings indicate the successful correction of early hematopoietic progenitor or stem cells that contributed quantitatively to all cell lineages of blood. We also confirmed correction of platelets on transplantation of retrovirus-transduced HSCs in humans.
In line with a proliferative advantage of WASP-positive cells,14 our results show increasing proportions of corrected lymphocytes over time. Since the reconstitution of the lymphoid system reaches a plateau, there continues to be homeostatic control. Engraftment of progenitor cells was stable, similar to the results achieved in a recent trial of lentivirus-based gene therapy for adrenoleukodystrophy,24 in which a completely myeloablative conditioning regimen was used.
The pathophysiology of thrombocytopenia in WAS is complex and involves decreased production of platelets and increased immune and nonimmune mechanisms of platelet destruction.25 This study provides evidence that gene transfer can correct thrombocytopenia in humans, a major cause of death and complications in patients with WAS.
The assessment of the clonal inventory in patients whose disease has been successfully corrected uncovers vector influence on key regulators of hematopoiesis. In addition, we observed preferential targeting of genes implicated in autoimmunity control, suggesting an unexpected, disease-related gene targeting. Most interestingly, insertion-site recovery in sorted lymphoid and myeloid fractions provides novel molecular evidence that the molecular signatures contributing to long-term production of hematologic cells are distinct in both cell lineages of WAS patients. These data suggest that distinctive mechanisms control selective proliferative advantage or differentiation of myeloid and lymphoid cells.
Despite targeting potential oncogenes, no persistent clonal imbalance has yet been observed. Deep sequencing revealed a fluctuating pattern of molecularly defined hematopoietic clones and evidence of initial transduction of HSCs with multilineage capacity, suggesting that hematopoiesis continues to follow a cyclic pattern. Clinically, both patients had marked improvement in their susceptibility to infection, autoimmunity, and bleeding. Longer follow-up and in-depth analyses in additional patients are warranted in light of the considerable clinical benefit derived from genetic correction of this disease. Hematopoietic stem-cell gene transfer may achieve complete immunologic correction without producing the toxic effects implicit in the concept of retrovirus-based stem-cell gene transfer.
Supported by grants from the Deutsche Forschungsgemeinschaft (DFG KliFo 110-2 and SPP1230) and the Bundesministerium für Bildung und Forschung (BMBF TreatID, BMBF PID-Net, and BMBF iGENE), the Sixth and Seventh Framework European Economic Community Program (CONSERT, PERSIST, and CLINIGENE), a grant (AI-067946) from the National Institutes of Health, TÁMOP (4.2.2-08/1-2008-0015), and a fellowship from the Else Kröner-Fresenius Stiftung (to Dr. Boztug).
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
We thank the patients and their families for their participation in this study and their openness to share the scientific data resulting from this clinical trial; all the physicians and nurses involved in this study; Paul Fisch of the University of Freiburg for help with TCR Vβ spectratyping; Roland Jacobs of Hannover Medical School for help with cytotoxicity assays; Anna Paruzynski and Christina Lulay of the National Center for Tumor Diseases (NCT) and the German Cancer Research Center (DKFZ), Heidelberg, for molecular analyses and data mining; Anne Arens of the NCT and DKFZ, Heidelberg, for bioinformatical analyses; Dr. Hans Ochs of the University of Washington, Seattle, for providing rabbit anti–WASP antibody; Ulrike Köhl of the University Hospital Frankfurt am Main for help with CD34+ cell purification; Jana Diestelhorst of Hannover Medical School for expert technical help; the Hannover Clinical Trial Center for monitoring the clinical trial; and the Care-for-Rare Foundation for its support.
Source Information
From the Department of Pediatric Hematology–Oncology (K.B., A.S., I.A.D., R.A.D., M.B., C. Klein) and the Institute for Transfusion Medicine (R.B.), Hannover Medical School, Hannover; the National Center for Tumor Diseases and German Cancer Research Center, Heidelberg (M.S., A.N., C.R.B., H.G., C. von Kalle); and EUFETS, Idar-Oberstein (S.N., K.K.) — all in Germany; Children's Hospital of Philadelphia Research Institute, Philadelphia (P.P.B., J.S.O.); the Department of Clinical Immunology, Russian Clinical Children's Hospital, Moscow (I.K.); and the Department of Infectious and Pediatric Immunology, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary (L.M.).
Address reprint requests to Dr. Klein at the Department of Pediatric Hematology–Oncology, Hannover Medical School, Carl Neuberg Str., 1 D-30625 Hannover, Germany, or at klein.christoph@mh-hannover.de.
- References
References
1
Puck JM ,Candotti F . Lessons from the Wiskott-Aldrich syndrome. N Engl J Med 2006;355:1759-1761
Full Text | Web of Science | Medline2
Notarangelo LD ,Miao CH ,Ochs HD . Wiskott-Aldrich syndrome. Curr Opin Hematol 2008;15:30-36
CrossRef | Web of Science | Medline3
Derry JM ,Ochs HD ,Francke U . Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 1994;78:635-644
CrossRef | Web of Science | Medline4
Thrasher AJ ,Burns SO . WASP: a key immunological multitasker. Nat Rev Immunol 2010;10:182-192
CrossRef | Web of Science | Medline5
Bosticardo M ,Marangoni F ,Aiuti A ,Villa A ,Grazia Roncarolo M . Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood 2009;113:6288-6295
CrossRef | Web of Science | Medline6
Imai K ,Morio T ,Zhu Y , et al. Clinical course of patients with WASP gene mutations. Blood 2004;103:456-464
CrossRef | Web of Science | Medline7
Ozsahin H ,Cavazzana-Calvo M ,Notarangelo LD , et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood 2008;111:439-445
CrossRef | Web of Science | Medline8
Cavazzana-Calvo M ,Hacein-Bey S ,de Saint Basile G , et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000;288:669-672
CrossRef | Web of Science | Medline9
Hacein-Bey-Abina S ,Le Deist F ,Carlier F , et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002;346:1185-1193
Full Text | Web of Science | Medline10
Aiuti A ,Slavin S ,Aker M , et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002;296:2410-2413
CrossRef | Web of Science | Medline11
Aiuti A ,Cattaneo F ,Galimberti S , et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009;360:447-458
Full Text | Web of Science | Medline12
Ott MG ,Schmidt M ,Schwarzwaelder K , et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006;12:401-409
CrossRef | Web of Science | Medline13
Boztug K ,Dewey RA ,Klein C . Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Curr Opin Mol Ther 2006;8:390-395
Web of Science | Medline14
Westerberg LS ,de la Fuente MA ,Wermeling F , et al. WASP confers selective advantage for specific hematopoietic cell populations and serves a unique role in marginal zone B-cell homeostasis and function. Blood 2008;112:4139-4147
CrossRef | Web of Science | Medline15
Klein C ,Nguyen D ,Lui C-H , et al. Gene therapy for Wiskott-Aldrich syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice. Blood 2003;101:2159-2166
CrossRef | Web of Science | Medline16
Dewey RA ,Avedillo Diez I ,Ballmaier M , et al. Retroviral WASP gene transfer into human hematopoietic stem cells reconstitutes the actin cytoskeleton in myeloid progeny cells differentiated in vitro. Exp Hematol 2006;34:1161-1169
CrossRef | Web of Science | Medline17
Orange JS ,Ramesh N ,Remold-O'Donnell E , et al. Wiskott-Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses. Proc Natl Acad Sci U S A 2002;99:11351-11356
CrossRef | Web of Science | Medline18
Humblet-Baron S ,Sather B ,Anover S , et al. Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasis. J Clin Invest 2007;117:407-418
CrossRef | Web of Science | Medline19
Schmidt M ,Schwarzwaelder K ,Bartholomae C , et al. High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). Nat Methods 2007;4:1051-1057
CrossRef | Web of Science | Medline20
Hacein-Bey-Abina S ,von Kalle C ,Schmidt M , et al. LMO2-associated clonal T-cell proliferations in two patients after gene therapy for SCID-X1. Science 2003;302:415-419[Erratum, Science 2003;302:568.]
CrossRef | Web of Science | Medline21
Hacein-Bey-Abina S ,Garrigue A ,Wang GP , et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008;118:3132-3142
CrossRef | Web of Science | Medline22
Howe SJ ,Mansour MR ,Schwarzwaelder K , et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008;118:3143-3150
CrossRef | Web of Science | Medline23
Stein S ,Ott MG ,Schultze-Strasser S , et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010;16:198-204
CrossRef | Web of Science | Medline24
Cartier N ,Hacein-Bey-Abina S ,Bartholomae CC , et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009;326:818-823
CrossRef | Web of Science | Medline25
Sabri S ,Foudi A ,Boukour S , et al. Deficiency in the Wiskott-Aldrich protein induces premature proplatelet formation and platelet production in the bone marrow compartment. Blood 2006;108:134-140
CrossRef | Web of Science | Medline
- Citing Articles (51)
Citing Articles
1
Luca Biasco, Cristina Baricordi, Alessandro Aiuti. (2012) Retroviral Integrations in Gene Therapy Trials. Molecular Therapy
CrossRef2
Sebastian Brennig, Ina Rattmann, Nico Lachmann, Axel Schambach, David A. Williams, Thomas Moritz. (2012) In vivo enrichment of cytidine deaminase gene-modified hematopoietic cells by prolonged cytosine-arabinoside application. Cytotherapy1-10
CrossRef3
Toru Uchiyama, Marsilio Adriani, G Jayashree Jagadeesh, Adam Paine, Fabio Candotti. (2012) Foamy Virus Vector-mediated Gene Correction of a Mouse Model of Wiskott–Aldrich Syndrome. Molecular Therapy
CrossRef4
Yunjoon Jung, Gerhard Bauer, Jan A. Nolta. (2012) Concise Review: Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells: Progress Toward Safe Clinical Products. STEM CELLS 30:1, 42-47
CrossRef5
Christian J. Buchholz, Ralf Sanzenbacher, Silke Schüle. (2012) The European Hospital Exemption Clause—New Option for Gene Therapy?. Human Gene Therapy 23:1, 7-12
CrossRef6
M Catucci, F Prete, M Bosticardo, M C Castiello, E Draghici, M Locci, M G Roncarolo, A Aiuti, F Benvenuti, A Villa. (2011) Dendritic cell functional improvement in a preclinical model of lentiviral-mediated gene therapy for Wiskott–Aldrich syndrome. Gene Therapy
CrossRef7
Claire Booth, H. Bobby Gaspar, Adrian J. Thrasher. (2011) Gene therapy for primary immunodeficiency. Current Opinion in Pediatrics 23:6, 659-666
CrossRef8
Matthew Porteus. (2011) Homologous recombination-based gene therapy for the primary immunodeficiencies. Annals of the New York Academy of Sciences 1246:1, 131-140
CrossRef9
Anne Galy, Adrian J. Thrasher. (2011) Gene therapy for the Wiskott–Aldrich syndrome. Current Opinion in Allergy and Clinical Immunology 11:6, 545-550
CrossRef10
Chuanfeng Wu, Cynthia E. Dunbar. (2011) Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity. Frontiers of Medicine 5:4, 356-371
CrossRef11
I. Riviere, C. E. Dunbar, M. Sadelain. (2011) Hematopoietic stem cell engineering at a crossroads. Blood
CrossRef12
C Brendel, U Müller-Kuller, S Schultze-Strasser, S Stein, L Chen-Wichmann, A Krattenmacher, H Kunkel, A Dillmann, M N Antoniou, M Grez. (2011) Physiological regulation of transgene expression by a lentiviral vector containing the A2UCOE linked to a myeloid promoter. Gene Therapy
CrossRef13
H Hosseini, D Y Oh, S T Chan, X T Chen, Z Nasa, H Yagita, F Alderuccio, B-H Toh, J Chan. (2011) Non-myeloablative transplantation of bone marrow expressing self-antigen establishes peripheral tolerance and completely prevents autoimmunity in mice. Gene Therapy
CrossRef14
Di Stasi, Antonio, Tey, Siok-Keen, Dotti, Gianpietro, Fujita, Yuriko, Kennedy-Nasser, Alana, Martinez, Caridad, Straathof, Karin, Liu, Enli, Durett, April G., Grilley, Bambi, Liu, Hao, Cruz, Conrad R., Savoldo, Barbara, Gee, Adrian P., Schindler, John, Krance, Robert A., Heslop, Helen E., Spencer, David M., Rooney, Cliona M., Brenner, Malcolm K., . (2011) Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy. New England Journal of Medicine 365:18, 1673-1683
Full Text15
Samantha L Ginn, Ian E Alexander. (2011) Gene therapy: Progress in childhood disease. Journal of Paediatrics and Child Healthno-no
CrossRef16
László Maródi, . (2011) The creation and progress of the J Project in Eastern and Central Europe. Annals of the New York Academy of Sciences 1238:1, 65-73
CrossRef17
Annette Deichmann, Martijn H Brugman, Cynthia C Bartholomae, Kerstin Schwarzwaelder, Monique MA Verstegen, Steven J Howe, Anne Arens, Marion G Ott, Dieter Hoelzer, Reinhard Seger, Manuel Grez, Salima Hacein-Bey-Abina, Marina Cavazzana-Calvo, Alain Fischer, Anna Paruzynski, Richard Gabriel, Hanno Glimm, Ulrich Abel, Claudia Cattoglio, Fulvio Mavilio, Barbara Cassani, Alessandro Aiuti, Cynthia E Dunbar, Christopher Baum, H Bobby Gaspar, Adrian J Thrasher, Christof von Kalle, Manfred Schmidt, Gerard Wagemaker. (2011) Insertion Sites in Engrafted Cells Cluster Within a Limited Repertoire of Genomic Areas After Gammaretroviral Vector Gene Therapy. Molecular Therapy 19:11, 2031-2039
CrossRef18
N Lachmann, J Jagielska, D Heckl, S Brennig, N Pfaff, T Maetzig, U Modlich, T Cantz, B Gentner, A Schambach, T Moritz. (2011) MicroRNA-150-regulated vectors allow lymphocyte-sparing transgene expression in hematopoietic gene therapy. Gene Therapy
CrossRef19
Inés Avedillo Díez, Daniela Zychlinski, Emanuele G. Coci, Melanie Galla, Ute Modlich, Ricardo A. Dewey, Adrian Schwarzer, Tobias Maetzig, Nonsikelelo Mpofu, Elmar Jaeckel, Kaan Boztug, Christopher Baum, Christoph Klein, Axel Schambach. (2011) Development of Novel Efficient SIN Vectors with Improved Safety Features for Wiskott–Aldrich Syndrome Stem Cell Based Gene Therapy. Molecular Pharmaceutics 8:5, 1525-1537
CrossRef20
Laurence Jeanson-Leh, Sabine Charrier, Alexis Proust, Chrystele Bilhou-Nabéra, Rémi Favier, Caroline Deswarte, Pierre Bordigoni, Anne Galy, Jean Delaunay. (2011) The c.273+11dup genetic change in the WAS gene is a functionally neutral polymorphism. European Journal of Haematology 87:4, 366-371
CrossRef21
Sebastian M. Dieter, Claudia R. Ball, Christopher M. Hoffmann, Ali Nowrouzi, Friederike Herbst, Oksana Zavidij, Ulrich Abel, Anne Arens, Wilko Weichert, Karsten Brand, Moritz Koch, Jürgen Weitz, Manfred Schmidt, Christof von Kalle, Hanno Glimm. (2011) Distinct Types of Tumor-Initiating Cells Form Human Colon Cancer Tumors and Metastases. Cell Stem Cell 9:4, 357-365
CrossRef22
Asher Mullard. (2011) Gene therapies advance towards finish line. Nature Reviews Drug Discovery 10:10, 719-720
CrossRef23
Jorge Mansilla-Soto, Isabelle Rivière, Michel Sadelain. (2011) Genetic strategies for the treatment of sickle cell anaemia. British Journal of Haematology 154:6, 715-727
CrossRef24
Rudi W Hendriks, Robbert GM Bredius, Karin Pike-Overzet, Frank JT Staal. (2011) Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man. Expert Opinion on Therapeutic Targets 15:8, 1003-1021
CrossRef25
Kelly Cox, Victoria Price, Walter HA Kahr. (2011) Inherited platelet disorders: a clinical approach to diagnosis and management. Expert Review of Hematology 4:4, 455-472
CrossRef26
Tao Wang, Jaydev R. Upponi, Vladimir P. Torchilin. (2011) Design of multifunctional non-viral gene vectors to overcome physiological barriers: Dilemmas and strategies. International Journal of Pharmaceutics
CrossRef27
M. Reiss, I.C. Büttel, C.K. Schneider. (2011) Erfahrungsbericht aus dem Ausschuss für neuartige Therapien (CAT). Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 54:7, 822-830
CrossRef28
C. Walter, B. Rohde, D.C. Wicke, C. Pohler, A. Lührmann, H. Leyen. (2011) Regulatorischer Rahmen für neuartige Therapien. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 54:7, 803-810
CrossRef29
L. M. Resar, R. A. Brodsky. (2011) "Let"-ing go with clonal expansion?. Blood 117:22, 5788-5790
CrossRef30
K. Ikeda, P. J. Mason, M. Bessler. (2011) 3'UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice. Blood 117:22, 5860-5869
CrossRef31
Marita Bosticardo, Elena Draghici, Francesca Schena, Aisha Vanessa Sauer, Elena Fontana, Maria Carmina Castiello, Marco Catucci, Michela Locci, Luigi Naldini, Alessandro Aiuti, Maria Grazia Roncarolo, Pietro Luigi Poliani, Elisabetta Traggiai, Anna Villa. (2011) Lentiviral-mediated gene therapy leads to improvement of B-cell functionality in a murine model of Wiskott-Aldrich syndrome. Journal of Allergy and Clinical Immunology 127:6, 1376-1384.e5
CrossRef32
Alain Fischer, Salima Hacein-Bey-Abina, Marina Cavazzana-Calvo. (2011) Gene therapy for primary adaptive immune deficiencies. Journal of Allergy and Clinical Immunology 127:6, 1356-1359
CrossRef33
Cecilia N. Barese, Cynthia E. Dunbar. (2011) Contributions of Gene Marking to Cell and Gene Therapies. Human Gene Therapy 22:6, 659-668
CrossRef34
Itai M. Pessach, Luigi D. Notarangelo. (2011) Gene therapy for primary immunodeficiencies: Looking ahead, toward gene correction. Journal of Allergy and Clinical Immunology 127:6, 1344-1350
CrossRef35
Seval Türkmen, Mathias Riehn, Eva Klopocki, Mara Molkentin, Richard Reinhardt, Thomas Burmeister. (2011) A BACH2-BCL2L1 fusion gene resulting from a t(6;20)(q15;q11.2) chromosomal translocation in the lymphoma cell line BLUE-1. Genes, Chromosomes and Cancer 50:6, 389-396
CrossRef36
Frank A. Giordano, Ursula R. Sorg, Jens-Uwe Appelt, Nico Lachmann, Stephanie Bleier, Ingo Roeder, Veronika Kleff, Michael Flasshove, W. Jens Zeller, Heike Allgayer, Christof von Kalle, Stefan Fruehauf, Thomas Moritz, Stephanie Laufs. (2011) Clonal Inventory Screens Uncover Monoclonality Following Serial Transplantation of MGMT P140K -Transduced Stem Cells and Dose-Intense Chemotherapy. Human Gene Therapy 22:6, 697-710
CrossRef37
A. Biffi, C. C. Bartolomae, D. Cesana, N. Cartier, P. Aubourg, M. Ranzani, M. Cesani, F. Benedicenti, T. Plati, E. Rubagotti, S. Merella, A. Capotondo, J. Sgualdino, G. Zanetti, C. von Kalle, M. Schmidt, L. Naldini, E. Montini. (2011) Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood 117:20, 5332-5339
CrossRef38
Takayuki Yokoi, Hiroshi Kobayashi, Yohta Shimada, Yoshikatsu Eto, Nobuyuki Ishige, Teruo Kitagawa, Makoto Otsu, Hiromitsu Nakauchi, Hiroyuki Ida, Toya Ohashi. (2011) Minimum requirement of donor cells to reduce the glycolipid storage following bone marrow transplantation in a murine model of Fabry disease. The Journal of Gene Medicine 13:5, 262-268
CrossRef39
V. Wahn, F. Zepp, M. Borte, W. Friedrich. (2011) Primäre Immundefekte. Monatsschrift Kinderheilkunde 159:5, 443-450
CrossRef40
Barbara Langer, Klaus Cichutek. (2011) Klinische Anwendung der Gentherapie. Bisherige Erfahrungen und Zukunft. Pharmazie in unserer Zeit 40:3, 254-262
CrossRef41
Grant D Trobridge. (2011) Genotoxicity of retroviral hematopoietic stem cell gene therapy. Expert Opinion on Biological Therapy 11:5, 581-593
CrossRef42
Mark A. Kay. (2011) State-of-the-art gene-based therapies: the road ahead. Nature Reviews Genetics 12:5, 316-328
CrossRef43
Joachim Schwäble, Stephan Schultze-Strasser, Stefan Stein, Manuel Grez. (2011) Gentherapie der septischen Granulomatose: Chancen und Risiken. Der Weg zur erfolgreichen Therapie einer angeborenen Immundefizienz. Pharmazie in unserer Zeit 40:3, 264-271
CrossRef44
Hildegard Büning. (2011) Gentherapie - Was ist das? “Heilen” mit Genen. Pharmazie in unserer Zeit 40:3, 194-201
CrossRef45
Luigi Naldini. (2011) Ex vivo gene transfer and correction for cell-based therapies. Nature Reviews Genetics 12:5, 301-315
CrossRef46
D. Heckl, D. C. Wicke, M. H. Brugman, J. Meyer, A. Schambach, G. Busche, M. Ballmaier, C. Baum, U. Modlich. (2011) Lentiviral gene transfer regenerates hematopoietic stem cells in a mouse model for Mpl-deficient aplastic anemia. Blood 117:14, 3737-3747
CrossRef47
Mike May. (2011) Mutations to the rescue. Nature Medicine 17:4, 405-407
CrossRef48
Derek A Persons, Christopher Baum. (2011) Solving the Problem of γ-Retroviral Vectors Containing Long Terminal Repeats. Molecular Therapy 19:2, 229-231
CrossRef49
(2011) Succès de thérapie génique dans une maladie rare. Revue Francophone des Laboratoires 2011:428, 24
CrossRef50
Alan Trounson, Rahul G Thakar, Geoff Lomax, Don Gibbons. (2011) Clinical trials for stem cell therapies. BMC Medicine 9:1, 52
CrossRef51
(2011) 2010 in reflection. Nature Reviews Drug Discovery 10:1, 7-9
CrossRef
